XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Net sales $ 691,099 $ 715,931 $ 1,391,161 $ 1,442,727
Cost of goods sold 295,118 314,333 591,620 640,502
Gross profit 395,981 401,598 799,541 802,225
Selling, general and administrative expense 208,730 213,425 406,324 439,278
Research and Development Expense 67,034 63,391 129,577 137,303
Segment profit (loss) 120,217 124,782 263,640 225,644
Interest expense 10,720 363 14,768 761
Foreign exchange (gains) losses, net 897 (1,761) (1,231) (1,690)
Marketable Securities, Unrealized (Gain) Loss 1,338,190 (1,030,691) 5,883,307 (2,210,094)
Other Nonoperating Income (Expense) 6,710 (96) 39,307 17,311
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (1,222,880) 1,156,775 (5,593,897) 2,453,978
(Provision) benefit for income taxes 295,696 (242,661) 1,297,100 (562,450)
Net income attributable to Bio-Rad $ (927,184) $ 914,114 $ (4,296,797) $ 1,891,528
Basic earnings per share:        
Net income per share basic attributable to Bio-Rad $ (31.12) $ 30.71 $ (143.88) $ 63.49
Weighted average common shares - basic 29,794 29,764 29,863 29,793
Diluted earnings per share:        
Net income per share diluted attributable to Bio-Rad $ (31.12) $ 30.32 $ (143.88) $ 62.70
Weighted average common shares - diluted 29,794 30,148 29,863 30,167